Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biosecurity

    UTHSC Awarded $3.2 Million for Upgrades to Regional Biocontainment Laboratory

    By Global Biodefense StaffOctober 5, 2021
    The Regional Biocontainment Laboratory (RBL) at UTHSC. Credit: Thurman Hobson
    Share
    Facebook LinkedIn Reddit Email

    The University of Tennessee Health Science Center has been awarded $3.2 million from the National Institute of Allergy and Infectious Diseases (NIAID) to upgrade the equipment and infrastructure in the UTHSC Regional Biocontainment Laboratory (RBL) on the Memphis campus to enhance the university’s research of infectious diseases, including COVID-19.

    Colleen Jonsson, PhD, Van Vleet Professor of Virology and director of the UTHSC Regional Biocontainment Laboratory, is the project director and principal investigator for the award that will fund improvements to the hardware and building automation system software, and provide state-of-the-art equipment for basic research and preclinical studies for testing of new therapeutics and vaccines.

    The RBL, a Biosafety Level 3 (BSL-3) lab, is among roughly a dozen across the country commissioned after 9/11 by the NIAID to study highly contagious pathogens in response to the threat of bioterrorism. It opened on the Memphis campus in 2009.

    Dr. Colleen Jonsson has spent her career working to unlock the secrets of some of the most virulent viruses on the planet. She is leading a team at UTHSC to develop an antiviral therapeutic for COVID-19. Photo by Brandon Dill

    “This will bring advanced preclinical imaging equipment into our Level 3 area,” Dr. Jonsson said. “This will enhance and strengthen our ability to learn more about infectious diseases in real time, such as COVID-19.”

    The RBL has played a key role in research related to the novel coronavirus. Dr. Jonsson has led teams of researchers sequencing the virus, working to determine possible antivirals to treat it, and developing COVID-19 diagnostic tools.

    The RBL received live virus samples of the coronavirus in late February 2020, which Dr. Jonsson and her team began testing against compounds (small molecules) that could be potential treatments. She collaborated with regional and national scientists and laboratories, including Oak Ridge National Laboratory, identifying several existing drugs as possible therapeutics for the virus. That collaboration continues.

    The RBL is also the site of UTHSC’s Center of Excellence in Encephalitic Alphavirus Therapeutics. In early 2019, Dr. Jonsson secured a $21 million National Institutes of Health grant to research antiviral treatments for deadly viruses that are spread to horses, and people, by infected mosquitoes.

    Alphavirus Awards BSL-3 Editor Pick NIAID Select Agents Zoonotic
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleEmerging Infectious Disease Caused By New Nairovirus Identified in Japan
    Next Article Vermont Air National Guard Partners with USDA for Rabies Vaccine Study

    Related Stories

    EPA Developing AMR Risk Framework for Antibacterial and Antifungal Pesticides

    September 29, 2023

    Provide Feedback on Federal DURC Biosafety Oversight of Potential Pandemic Pathogens

    September 24, 2023

    Committee to Examine Transmission and Geographic Spread of Chronic Wasting Disease

    September 24, 2023

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.